Sana Biotechnology (NASDAQ:SANA) Shares Down 11.1% – Should You Sell?

Sana Biotechnology, Inc. (NASDAQ:SANA) shares traded down 11.1% during trading on Thursday . The stock traded as low as $3.15 and last traded at $3.1550. Approximately 2,231,136 shares were traded during mid-day trading, a decline of 31% from the average daily volume of 3,229,869 shares. The stock had previously closed at $3.55.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on SANA shares. Rodman & Renshaw assumed coverage on Sana Biotechnology in a report on Monday, May 11th. They set a “buy” rating and a $16.00 target price for the company. Wedbush lifted their price target on Sana Biotechnology from $6.00 to $7.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 14th. Weiss Ratings downgraded Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. Finally, Wall Street Zen raised Sana Biotechnology from a “sell” rating to a “hold” rating in a research note on Sunday. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $9.50.

Sana Biotechnology Trading Down 10.8%

The firm has a fifty day simple moving average of $3.28 and a two-hundred day simple moving average of $3.62. The firm has a market cap of $880.79 million, a PE ratio of -3.40 and a beta of 2.13.

Sana Biotechnology (NASDAQ:SANA) last posted its earnings results on Monday, May 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.01. Equities analysts expect that Sana Biotechnology, Inc. will post -0.59 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in SANA. Royal Bank of Canada raised its holdings in Sana Biotechnology by 76.8% in the 1st quarter. Royal Bank of Canada now owns 12,285 shares of the company’s stock worth $35,000 after purchasing an additional 5,338 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in shares of Sana Biotechnology during the 3rd quarter valued at about $36,000. Rockefeller Capital Management L.P. boosted its stake in shares of Sana Biotechnology by 74.3% during the 4th quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock valued at $39,000 after purchasing an additional 4,088 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Sana Biotechnology during the third quarter valued at about $39,000. Finally, LRI Investments LLC purchased a new position in shares of Sana Biotechnology during the fourth quarter valued at about $41,000. 88.23% of the stock is owned by hedge funds and other institutional investors.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.